Wall Street and Silicon Valley investors recently piled into a $30-million psychedelics fund-raising initiative.
Entheon Biomedical
Company Brief
Entheon Biomedical seeks to research, develop, patent, and distribute psilocybin and DMT based medicines and treatments for those suffering from substance-abuse disorders.This under-serviced market was valued at US$ 13.22 Billion in 2016, and is expected to grow to US$ 27.91 Billion by 2025.
Highlights
Related Articles
Wuhan General Group Corporate Update
Wuhan General (soon to be M2Bio Sciences) has released a corporate update on its psychedelics and cannabis operations.
TSI EDITOR |
2020-08-21
ATAI Life Sciences Forges Premier Psychedelics R&D Platform
ATAI Life Sciences is preparing to add three new drug development partners as it builds the premier R&D platform in the psychedelics space.
TSI EDITOR |
2020-06-19
IntelGenx Enters into Feasibility Agreement with ATAI Life Sciences to Develop Pharmaceutical-Grade Polymeric Film-Based Psychedelics
IntelGenX enters into agreement with ATAI Life Sciences to develop novel formulations of pharmaceutical-grade psychedelics.
TSI EDITOR |
2020-08-20
PSYC Establishes New Partnership with Industry Leader, Microdose Psychedelic Insights
Global Trac Solutions is developing a media partnership with Microdose.
TSI EDITOR |
2020-08-19
Mydecine™ Launches World's First Natural-Sourced cGMP Psilocybin for Global Research, Sales, and Distribution Enterprise
Mydecine is ready to start supplying GMP-quality psilocybin to advance psychedelics R&D.
TSI EDITOR |
2020-08-18
Latest Stories
NEW BULL MARKET ALERT
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now